Cost estimation of cardiovascular disease events in the US

PharmacoEconomics

Volumn 29, Issue 8, 2011, Pages 693-704

  O'Sullivan, Amy K ^a   Rubin, Jaime ^a   Nyambose, Joshua ^a   Kuznik, Andreas ^b   Cohen, David J ^c   Thompson, David ^a  

^a i3 Global   (Canada)

^b PFIZER INC   (United States)

^c SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

Author keywords

Angina pectoris; Cardiovascular disorders; Cost analysis; Myocardial infarction; Stroke

Indexed keywords

ADULT; ANGINA PECTORIS; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; STROKE; TRANSIENT ISCHEMIC ATTACK; UNITED STATES;

AGED; CARDIOVASCULAR DISEASES; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; FEMALE; HEALTH CARE COSTS; HOSPITAL COSTS; HUMANS; LINEAR MODELS; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; PROPENSITY SCORE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TIME FACTORS; UNITED STATES;

EID: 79960145526     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11584620-000000000-00000     Document Type: Article

References (26)

1. Framingham Heart Study. A project of thehj National Heart, Lung, and Blood Institute and Boston University [online]. Available from URL: http://www.framinghamheartstudy.org [Accessed 2008 Nov 1]
2. Anderson KM, Odell PM, Wilson PWF, et al. Cardiovascular disease profiles. Am Heart J 1990; 121: 293-8
3. Anderson KM, Wilson PWF, Odell PM, et al. An updated coronary risk profile: a statement for health professionals. Circulation 1991; 83 (1): 356-62
4. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham Heart Study. Am Heart J 2000 Feb; 139: 272-81 (Pubitemid 30090804)
5. Weinstein MC, Coxson PG, Williams LW, et al. Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. Am J Public Health 1987; 77: 1417-26 (Pubitemid 18011588)
6. Grover SA, Abrahamowicz M, Joseph L, et al. The benefits of treating hypercholesterolemia to prevent coronary heart disease: estimating changes in life expectancy and morbidity. JAMA 1992; 267: 816-22
7. Babad H, Sanderson C, Nafgidoo B, et al. The development of a simulation model of primary prevention strategies for coronary heart disease. Health Care Manag Sci 2002; 5: 269-74 (Pubitemid 41450972)
8. Cooper K, Davies R, Roderick P, et al. The development of a simulation model of the treatment of coronary heart disease. Health Care Manag Sci 2002; 5: 259-67 (Pubitemid 41450971)
9. Birnbaum H, Leong S, Kabra A. Lifetime medical costs for women: cardiovascular disease, diabetes, and stress urinary incontinence. Womens Health Issues 2003; 13 (6): 204-13 (Pubitemid 37522251)
10. Russell MW, Huse DM, Drowns S, et al. Direct medical costs of coronary artery disease in the US. Am J Cardiol 1998; 81: 1110-5
11. Taylor TN, Davis PH, Torner JC, et al. Lifetime cost of stroke in the US. Stroke 1996; 27: 1459-66
12. Lee WC, Christensen MC, Joshi AV, et al. Long-term costs of stroke subtypes among Medicare beneficiaries. Cerebrovasc Dis 2007; 23: 57-65 (Pubitemid 46112803)
13. Mark DB, Knight JD, Cowper PA, et al. Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating New Targets (TNT) trial. Am Heart J 2008; 156: 698-705
14. Miller PS, Smith DG, Jones P. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial). Am J Cardiol 2005; 95: 1314-9 (Pubitemid 40719862)
15. TaylorDC, PandyaA, ThompsonD, et al.Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating New Targets Study. Eur J Health Econ 2009 Jul; 10: 255-65
16. Ramsey SD, Clarke LD, Roberts CS, et al. An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes. Pharmacoeconomics 2008; 26: 329-39 (Pubitemid 351457479)
17. Hartunian NS, Smart CN, Thompson MS. The incidence and economic costs of cancer,motor vehicle injuries, coronary heart disease, and stroke: a comparative analysis. Am J Public Health 1980; 70: 1249-60 (Pubitemid 11238812)
18. Dennis MS, Burn JPS, Sandercock PAG, et al. Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke 1993; 24: 796-800 (Pubitemid 23163551)
19. Lampe FC, Whincup PH, Wannamethee SG, et al. The natural history of prevalent ischaemic heart disease in middle-aged men. Eur Heart J 2000; 21: 1052-62 (Pubitemid 30352989)
20. Mosterd A, Cost B, Hoes AW, et al. The prognosis of heart failure in the general population. EurHeart J 2001; 22: 1318-27 (Pubitemid 32737624)
21. Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika 1993; 70: 41-55
22. D'Agostino Jr RB. Tutorial in biostatistics: propensity score methods for bias reduction in comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-81
23. Coca-Perraillon M. Local and global optimal propensity score matching [paper 185-2007]. SAS Global Forum, 2007 [online]. Available from URL: http://www.biostat.umn.edu/~will/6470stuff/Class25-10/SAS%20matching%202007.pdf [Accessed 2011 Mar 24]
24. Mullahy J. Much ado about two: reconsidering retransformation and two-part models in health econometrics. J Health Econ 1998; 17: 247-81 (Pubitemid 28300216)
25. Buntin MB, Zaslavsky AM. Too much ado about twopart models and transformation? Comparing methods of modeling Medicare expenditures. J Health Econ 2004; 23: 525-42 (Pubitemid 38569537)
26. Kruse M, Davidsen M, Madsen M, et al. Costs of heart disease and risk behaviour: implications for expenditure on prevention. Scand J Public Health 2008; 36: 850-6